Prolium

Developer of therapies targeting autoimmune diseases using T-cell engager technology

placeNew York City, New York, United States calendar_todayFounded 2025 language proliumbio.com

Investor mix

1 investor on record.

Investor typeCountShare
Venture capital1100%

Hiring activity

Hires periodically

8 roles tracked across 3 of the last 12 months

20 Dec 2025 · Project Coordinator · Airdrie

17 Dec 2025 · Project Manager · Airdrie

27 Nov 2025 · Design Engineer · Airdrie

18 Oct 2025 · Equipment Operator · Hamilton

11 Oct 2025 · Quality Control · Hamilton

Based on job postings tracked across public sources.

Coming soon